Gao et al. examined GL261 cell lines of mouse glioma cells using duloxetine in a dose-dependent manner (30 mg/kg) by way of oral feeding for 14 days and concluded that duloxetine has the potential to suppress S100B production as well as the inhibition of GL261 glioma cell proliferation within the cranium [113]. Here, S100B is linked to central nervous system cancer.